

## Underwritten Offering: End of Stabilisation Period

**MINNEAPOLIS, United States and BRISBANE, Australia February 25, 2026 (AEST): Anteris Technologies Global Corp. (Anteris or the Company)** (NASDAQ: AVR, ASX: AVR) a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function provides the following disclosure as required by the 'no-action letter' issued by the Australian Securities and Investments Commission on January 20, 2026 in connection with the Company's underwritten public offering which closed on January 22, 2026 US Eastern Time (**Offering**) (**No Action Letter**).

### Exercise of Underwriters' Option

As announced to ASX on January 23, 2026 AEST, Barclays Capital Inc., Wells Fargo Securities, LLC and Cantor Fitzgerald & Co., (the **Underwriters' Representatives**) fully exercised the underwriters' option granted by the Company in respect of 5,217,391 shares of common stock of the Company (**Common Stock**) at the purchase price of US\$5.75 per share, less underwriting discounts and commission of \$0.29325 per share.

### End of Stabilisation Period

The Company confirms that Wells Fargo Securities LLC (**Stabilisation Manager**) did not undertake any market stabilisation activities in the market stabilisation period, which ended on February 22, 2026 US Eastern Time. The Stabilisation Manager did not acquire any Common Stock in the market stabilisation period.

### ENDS

### About Anteris

Anteris Technologies Global Corp. (NASDAQ: AVR, ASX: AVR) is a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function. Founded in Australia, with a significant presence in Minneapolis, USA, Anteris is a science-driven company with an experienced team of multidisciplinary professionals delivering restorative solutions to structural heart disease patients.

Anteris' lead product, the DurAVR<sup>®</sup> Transcatheter Heart Valve (**THV**), was designed in collaboration with the world's leading interventional cardiologists and cardiac surgeons to treat aortic stenosis – a potentially life-threatening condition resulting from the narrowing of the aortic valve. The balloon-expandable DurAVR<sup>®</sup> THV is the first biomimetic valve, which is shaped to mimic the performance of a healthy human aortic valve and aims to replicate normal aortic blood flow. DurAVR<sup>®</sup> THV is made using a single piece of molded ADAPT<sup>®</sup> tissue, Anteris' patented anti-calcification tissue technology. ADAPT<sup>®</sup> tissue, which is FDA-cleared, has been used clinically for over 10 years and distributed for use in over 55,000 patients worldwide. The DurAVR<sup>®</sup> THV System is comprised of the DurAVR<sup>®</sup> valve, the ADAPT<sup>®</sup> tissue, and the balloon-expandable ComASUR<sup>®</sup> Delivery System.



### **Authorisation and Additional information**

This announcement was authorised for release on the ASX by Wayne Paterson, Vice Chairman and Chief Executive Officer.

### **For more information:**

#### **Investor Relations**

investors@anteristech.com  
Debbie Ormsby  
Anteris Technologies Global Corp.  
+61 1300 550 310 | +61 7 3152 3200

#### **Investor Relations (US)**

mchatterjee@bplifescience.com  
Malini Chatterjee, Ph.D.  
Blueprint Life Science Group  
+1 917 330 4269

Website      [www.anteristech.com](http://www.anteristech.com)  
X              @AnterisTech  
LinkedIn     <https://www.linkedin.com/company/anteristech>